Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Prognostic scores for chronic lymphocytic leukemia (CLL) may overestimate disease progression risk in patients with chronic kidney disease (CKD). Beta-2-microglobulin
Area Of Science
- Hematology
- Oncology
- Nephrology
Background
- Chronic lymphocytic leukemia (CLL) exhibits a heterogeneous clinical course.
- Prognostic scores like CLL-IPI and OCLL-1 predict treatment timelines.
- Elevated beta-2-microglobulin (B2M) is a prognostic factor in CLL but also common in chronic kidney disease (CKD).
Purpose Of The Study
- To evaluate the prognostic accuracy of CLL-IPI and OCLL-1 scores in CLL patients with CKD.
- To determine if B2M retains prognostic significance in CLL patients with CKD.
Main Methods
- Analysis of clinical outcomes in 297 treatment-naive CLL patients (2000-2022).
- Comparison of prognostic score performance between CKD and non-CKD patients.
- Assessment of B2M levels and prognostic significance in CKD patients.
Main Results
- B2M was more frequently elevated in CKD patients.
- B2M lost prognostic significance at > 2.5 mg/L in CKD patients.
- CLL-IPI and OCLL-1 scores failed to accurately stratify risk in CKD patients, with 22.2% misclassified due to elevated B2M.
Conclusions
- CLL prognostic scores (CLL-IPI, OCLL-1) may overestimate disease progression risk in CKD patients.
- These scores require cautious interpretation in CLL patients with co-existing CKD.
- Further refinement of prognostic models for CLL patients with CKD is warranted.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
